27 August 2019 : Meta-Analysis
Intra-Articular Viscosupplementation for Patients with Hip Osteoarthritis: A Meta-Analysis and Systematic ReviewYing-Yang Liao12BCEFG, Tiao Lin1ABCDEFG*, Han-Xiao Zhu3BCE, Ming-Min Shi3BCF, Shi-Gui Yan3ADE
Med Sci Monit 2019; 25:6436-6445
BACKGROUND: The aim of this study was to review the efficacy and safety of intra-articular (IA) viscosupplementation (VS) for hip osteoarthritis (OA).
MATERIAL AND METHODS: We searched Medline, Clinical Trial Register Center, EMBASE, and Cochrane databases for randomized controlled trials (RCTs) comparing VS with placebo injection for hip OA. We included suitable studies, assessed the quality of studies, and extracted data on pain reduction, function improvement at different time points, and safety profiles. The comparisons of pain and function outcome were performed by meta-analysis.
RESULTS: Five high-quality randomized controlled studies trials (RCTs) with 591 patients with hip OA were identified. Although several trials demonstrated a significant decline in pain in VS groups during follow-up compared to baseline, without severe adverse events, the pooled analysis did not show VS was superior to placebo at any time windows [7–14 days: standardized mean difference (SMD): –0.18; 95% CI, –0.47 to 0.10, p=0.21; 28–30 days: 0.02 (–0.15, 0.19), p=0.82; or at final visit: –0.14 (–0.46, 0.18), p=0.38]. Similar results were also observed in the combined data of functional results.
CONCLUSIONS: IA VS does not reduce pain or improve function significantly better than placebo in a short-term follow-up. The benefits and safety of VS should be further assessed by sufficiently-sized, methodologically sound studies with validated assessment of more clinically relevant end-points.
Keywords: meta-analysis, Osteoarthritis, Hip, Pain Measurement, viscosupplementation, Clinical Trials as Topic, Injections, Intra-Articular, Pain, Quality Assurance, Health Care, Treatment Outcome
01 December 2022 : EditorialEditorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Fungal Pathogens During the COVID-19 Pandemic
Med Sci Monit 2022; 28:e939088
29 November 2022 : Clinical ResearchRetrospective Study to Identify Risk Factors for Severe Disease and Mortality Using the Modified Early Warn...
Med Sci Monit In Press; DOI: 10.12659/MSM.938647
24 November 2022 : Clinical ResearchA Prospective Questionnaire-Based Study to Evaluate Factors Affecting the Decision to Receive COVID-19 Vacc...
Med Sci Monit In Press; DOI: 10.12659/MSM.938665
01 December 2022 : EditorialEditorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Funga...
Med Sci Monit 2022; 28:e939088
05 Dec 2022 : Database AnalysisImpact of the De Ritis Ratio on the Prognosis of Patients with Stable Coronary Artery Disease Undergoing Pe...
Med Sci Monit In Press; DOI: 10.12659/MSM.937737
02 Dec 2022 : Clinical ResearchValue of Early Laparoscopic Exploration for Primary Infertile Patients with Patent Fallopian Tubes Complica...
Med Sci Monit In Press; DOI: 10.12659/MSM.938637
02 Dec 2022 : Clinical ResearchSingle-Center Study in Lithuania to Evaluate the Role of Transthoracic Impedance Cardiography in the Diagno...
Med Sci Monit In Press; DOI: 10.12659/MSM.938389
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
01 Nov 2020 : Review articleLong-Term Respiratory and Neurological Sequelae of COVID-19
Med Sci Monit 2020; 26:e928996